Glioblastoma vulnerability to neddylation inhibition is dependent on PTEN status, and dysregulation of the cell cycle and DNA replication

• Published in: Neuro-oncology advances Vol. 6; no. 1; p. vdae104
• Main Authors: Taylor, Brett, Tang, Nanyun, Hao, Yue, Lee, Matthew, Peng, Sen, Bybee, Rita, Hartman, Lauren, Garcia-Mansfield, Krystine, Sharma, Ritin, Pirrotte, Patrick, Ma, Jianhui, Parisian, Alison D, Furnari, Frank, Dhruv, Harshil D, Berens, Michael E
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.01.2024
• Subjects: Basic and Translational Investigations
• ISSN: 2632-2498; 2632-2498
• DOI: 10.1093/noajnl/vdae104

Abstract Background Neddylation (NAE) inhibition, affecting posttranslational protein function and turnover, is a promising therapeutic approach to cancer. We report the cytotoxic vulnerability to NAE inhibitors in a subset of glioblastoma (GBM) preclinical models and identify genetic alterations and biological processes underlying differential response. Methods GBM DNA sequencing and transcriptomic data were queried for genes associated with response to NAE inhibition; candidates were validated by molecular techniques. Multi-omics and functional assays revealed processes implicated in NAE inhibition response. Results Transcriptomics and shotgun proteomics depict PTEN signaling, DNA replication, and DNA repair pathways as significant differentiators between sensitive and resistant models. Vulnerability to MLN4924, a NAE inhibitor, is associated with elevated S-phase populations, DNA re-replication, and DNA damage. In a panel of GBM models, loss of WT PTEN is associated with resistance to different NAE inhibitors. A NAE inhibition response gene set could segregate the GBM cell lines that are most resistant to MLN4924. Conclusions Loss of WT PTEN is associated with non-sensitivity to 3 different compounds that inhibit NAE in GBM. A NAE inhibition response gene set largely consisting of DNA replication genes could segregate GBM cell lines most resistant to NAEi and may be the basis for future development of NAE inhibition signatures of vulnerability and clinical trial enrollment within a precision medicine paradigm.